Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals (NASDAQ: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for oncology and obesity, has announced equity inducement grants to two new employees. The grants, approved under the 2022 Employment Inducement Award Plan and in compliance with Nasdaq Listing Rule 5635(c)(4), include:
- Options to purchase 325,000 shares of Terns common stock - Exercise price of $3.56 per share (closing price on May 1, 2025) - 10-year term options - Four-year vesting period, contingent on continued employment
Terns Pharmaceuticals (NASDAQ: TERN), una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di trattamenti a piccola molecola per oncologia e obesità, ha annunciato l'assegnazione di incentivi azionari a due nuovi dipendenti. Le concessioni, approvate nell'ambito del Piano di Incentivi per l'Assunzione 2022 e conformi alla Regola Nasdaq 5635(c)(4), comprendono:
- Opzioni per l'acquisto di 325.000 azioni ordinarie di Terns
- Prezzo di esercizio di 3,56 $ per azione (prezzo di chiusura del 1° maggio 2025)
- Opzioni con durata di 10 anni
- Periodo di maturazione di quattro anni, subordinato alla continuazione del rapporto di lavoro
Terns Pharmaceuticals (NASDAQ: TERN), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de tratamientos de pequeñas moléculas para oncología y obesidad, ha anunciado concesiones de incentivos accionarios a dos nuevos empleados. Las concesiones, aprobadas bajo el Plan de Incentivos por Empleo 2022 y en cumplimiento con la Regla de Listado Nasdaq 5635(c)(4), incluyen:
- Opciones para comprar 325,000 acciones comunes de Terns
- Precio de ejercicio de $3.56 por acción (precio de cierre al 1 de mayo de 2025)
- Opciones con un plazo de 10 años
- Período de adquisición de derechos de cuatro años, condicionado a la continuidad del empleo
Terns Pharmaceuticals (NASDAQ: TERN)는 종양학 및 비만 치료를 위한 소분자 신약 개발에 주력하는 임상 단계 바이오제약 회사로, 두 명의 신입 직원에게 주식 인센티브를 부여했다고 발표했습니다. 이 인센티브는 2022년 고용 유인상 계획에 따라 승인되었으며 Nasdaq 상장 규칙 5635(c)(4)를 준수합니다. 세부 내용은 다음과 같습니다:
- Terns 보통주 325,000주 매수 옵션
- 주당 행사 가격 $3.56 (2025년 5월 1일 종가 기준)
- 10년 만기 옵션
- 4년 베스팅 기간, 계속 고용 조건부
Terns Pharmaceuticals (NASDAQ : TERN), une société biopharmaceutique en phase clinique spécialisée dans le développement de traitements par petites molécules pour l'oncologie et l'obésité, a annoncé l'attribution de subventions d'incitation en actions à deux nouveaux employés. Ces subventions, approuvées dans le cadre du Plan d'Attribution d'Incitations à l'Emploi 2022 et conformes à la règle Nasdaq 5635(c)(4), comprennent :
- Options d'achat de 325 000 actions ordinaires de Terns
- Prix d'exercice de 3,56 $ par action (cours de clôture au 1er mai 2025)
- Options d'une durée de 10 ans
- Période d'acquisition de quatre ans, conditionnée à la poursuite de l'emploi
Terns Pharmaceuticals (NASDAQ: TERN), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf die Entwicklung von Kleinmolekültherapien für Onkologie und Adipositas, hat Aktienanreiz-Zuteilungen an zwei neue Mitarbeiter angekündigt. Die Zuteilungen, genehmigt im Rahmen des 2022 Employment Inducement Award Plans und in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4), umfassen:
- Optionen zum Kauf von 325.000 Aktien der Terns-Stammaktien
- Ausübungspreis von 3,56 $ pro Aktie (Schlusskurs am 1. Mai 2025)
- Optionen mit einer Laufzeit von 10 Jahren
- Vierjähriger Vesting-Zeitraum, abhängig von fortgesetzter Beschäftigung
- None.
- None.
FOSTER CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of May 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees’ acceptance of employment with Terns.
The Company granted options to purchase 325,000 shares, in the aggregate, of Terns common stock to the new employees. The options have a 10-year term and an exercise price per share equal to
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Kaytee Bock Zafereo
investors@ternspharma.com
Media
Jenna Urban
CG Life
media@ternspharma.com
FAQ
What equity inducement grants did TERN announce on May 2, 2025?
What is the vesting period for TERN's employee stock options granted in May 2025?
What was the exercise price for TERN's inducement grants announced in May 2025?
How many new employees received stock options from TERN in the May 2025 grant?
